View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen Inc., Pfizer, Inc., and Takeda Oncology.

ASH: Medical Crossfire®: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think and Treat

ASH: Medical Crossfire®: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think and Treat

Friday, December 6, 2019
1:30 PM – 4:30 PM
Lunch and Registration: 12:30 PM – 1:30 PM

Hyatt Regency Orlando
Lunch: Plaza H, Convention Level
Meeting Room: Plaza H, Convention Level
9801 International Drive
Orlando, FL 32819
Phone: (407) 284-1234


There remain unique treatment challenges among adolescent and young adult (AYA) and adult patients with acute lymphoblastic leukemia (ALL), including matching optimized front-line induction strategies to the patient, and the management of relapsed or refractory disease. Substantial advances in understanding ALL pathology, including evolving applications for cytogenetic and molecular abnormality characteristics, have allowed for the development and incorporation of novel targeted and immune strategies into the field in recent years. Similarly, advances in testing technologies’ sensitivity allows for improved risk stratification and monitoring of patients who receive treatment for these hematologic malignancies. Moreover, uses for minimal residual disease (MRD) assessment in clinical trials and patient management continue to expand. All of these advances have facilitated more personalized approaches that are now based on immunophenotypic, cytogenetic, and molecular features. Each of these patient- and tumor-specific features are considered now in state-of-the-art risk stratification and ALL treatment planning.

Medical Crossfire® provides an unparalleled educational format for experts and ALL care team members to engage in an exciting interchange of evidence-based viewpoints and practices facilitated by a case-based agenda grounded in real-world ALL care scenarios. The educational design of this format not only allows attendees access to renowned expert opinions, but also grants time for attendees to reflect on how they may clinically manage similar cases in the context of recent landmark evidence and evolving management paradigms. The focus of faculty discussion of these case scenarios is on factors that may impact risk stratification and treatment decision making; best practices to apply emerging treatment approaches in ALL treatment; and strategies to proactively plan for, and mitigate the impact on outcomes of, treatment-related toxicities.

Benefits of Attending:

  • Gain an understanding of recent evidence that allows you to optimize clinical decision-making for your patients with ALL
  • Hear from the experts on how they approach ALL cases you typically encounter in your clinical practice
  • Learn cutting-edge testing strategies, including evolving roles for MRD, in monitoring and treatment planning among patients with ALL
  • Compare your practices with those of the experts in caring for your adolescent and young adults, as well as other adult populations, with ALL

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen Inc., Pfizer, Inc., and Takeda Oncology.

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with ALL. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

  • Outline risk stratification strategies in ALL to help develop appropriate treatment plans through cytogenetic and immunophenotypic studies
  • Evaluate the clinical utility of MRD assessment and how this may inform prognosis and treatment planning for AYA populations and adults with ALL
  • Define the role of emerging therapies for the management of ALL, including monoclonal antibodies, antibody conjugates, and CAR T-cell therapies
  • Recognize groups of patients who may be eligible for emerging ALL treatment approaches

Program Chair

Elias Jabbour
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

ASH CME Programs


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By